
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          Rheumatoid_NNP arthritis_NN (_( RA_NNP )_) is_VBZ a_DT chronic_JJ systemic_JJ
          autoimmune_JJ disease_NN that_WDT is_VBZ characterized_VBN by_IN joint_JJ
          inflammation_NN ,_, and_CC progressive_JJ cartilage_NN and_CC bone_NN erosion_NN ._.
          Recent_JJ research_NN has_VBZ identified_VBN certain_JJ biologic_JJ agents_NNS
          that_WDT appear_VBP more_RBR able_JJ than_IN conventional_JJ therapies_NNS to_TO halt_VB
          effectively_RB the_DT progression_NN of_IN disease_NN ,_, as_RB well_RB as_IN
          ameliorate_NN disease_NN symptoms_NNS ._. One_CD potential_JJ problem_NN with_IN
          the_DT use_NN of_IN biologic_JJ agents_NNS for_IN arthritis_NN therapy_NN is_VBZ the_DT
          need_NN for_IN daily_JJ or_CC weekly_JJ repeat_NN dosing_VBG ._. The_DT transfer_NN of_IN
          genes_NNS directly_RB to_TO the_DT synovial_NN lining_NN can_MD theoretically_RB
          circumvent_VB the_DT need_NN for_IN repeat_NN dosing_VBG and_CC reduce_VB
          potential_JJ systemic_JJ side_NN effects_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. However_RB ,_,
          although_IN many_JJ genes_NNS have_VBP been_VBN effective_JJ in_IN treating_VBG
          murine_NN CIA_NNP if_IN administrated_JJ at_IN a_DT time_NN before_IN disease_NN
          onset_NN ,_, local_JJ intra-articular_JJ or_CC periarticular_NN gene_NN
          transfer_NN has_VBZ not_RB been_VBN highly_RB effective_JJ in_IN halting_VBG the_DT
          progression_NN of_IN established_VBN disease_NN ._. IL-_NNP 4_CD ,_, similar_JJ to_TO
          tumor_NN necrosis_NNS factor_NN (_( TNF_NNP )_) -_: α_NN and_CC IL-_NNP 1_CD inhibitors_NNS ,_, has_VBZ
          been_VBN shown_VBN be_VB therapeutic_JJ for_IN the_DT treatment_NN of_IN murine_NN CIA_NNP
          when_WRB administered_VBN intravenously_RB as_IN a_DT recombinant_JJ protein_NN ,_,
          either_CC alone_RB or_CC in_IN combination_NN with_IN IL-_NNP 10_CD ._. IL-_NNP 4_CD can_MD
          downregulate_NN the_DT production_NN of_IN proinflammatory_NN and_CC
          T-_NNP helper_NN (_( Th_NNP )_) 1_CD -_: type_NN cytokines_NNS by_IN inducing_VBG mRNA_NN
          degradation_NN and_CC upregulating_VBG the_DT expression_NN of_IN inhibitors_NNS
          of_IN proinflammatory_NN cytokines_NNS such_JJ as_IN IL-_NNP 1_CD receptor_NN
          antagonist_NN (_( IL-_NNP 1_CD Ra_NNP )_) [_NN 3_CD ,_, 4_CD ]_NN ._. IL-_NNP 4_CD is_VBZ able_JJ to_TO inhibit_VB IL-_NNP 2_CD
          and_CC IFN-γ_NNP production_NN by_IN Th_NNP 1_CD cells_NNS ,_, resulting_VBG in_IN
          suppression_NN of_IN macrophage_NN activation_NN and_CC the_DT production_NN
          of_IN the_DT proinflammatory_NN cytokines_NNS IL-_NNP 1_CD ,_, IL-_NNP 6_CD ,_, IL-_NNP 8_CD ,_, and_CC
          TNF-α_NNP by_IN monocytes_NNS and_CC macrophages_NNS [_NN 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_,
          9_CD ]_NN ._.
        
        
          Objective_NNP
          In_IN order_NN to_TO examine_VB the_DT therapeutic_JJ effects_NNS of_IN local_JJ
          and_CC systemic_JJ IL-_NNP 4_CD expression_NN in_IN established_VBN CIA_NNP ,_, an_DT
          adenoviral_NN vector_NN carrying_VBG the_DT gene_NN for_IN murine_NN IL-_NNP 4_CD
          (_( Ad-m_NNP IL-_NNP 4_LS )_) was_VBD generated_VBN ._. The_DT ability_NN of_IN Ad-m_NNP IL-_NNP 4_CD to_TO
          treat_VB established_VBN CIA_NNP was_VBD evaluated_VBN by_IN local_JJ
          periarticular_NN and_CC systemic_JJ intravenous_JJ injection_NN of_IN
          Ad-m_NNP IL-_NNP 4_CD into_IN mice_NNS at_IN various_JJ times_NNS after_IN disease_NN
          onset_NN ._.
        
        
          Materials_NNS and_CC methods_NNS
          Male_NNP DBA_NNP /_NN 1_CD lacJ_NN (_( H-_NNP 2_CD 
          q_NN )_) mice_NNS ,_, aged_VBN 7_CD -_: 8_CD weeks_NNS ,_, were_VBD
          purchased_VBN from_IN The_DT Jackson_NNP Laboratory_NNP (_( Bar_NNP Harbor_NNP ,_, ME_NNP ,_,
          USA_NNP )_) ._. The_DT mice_NNS were_VBD immunized_JJ intradermally_RB at_IN the_DT base_NN
          of_IN tail_NN with_IN 100_CD μ_NN g_SYM bovine_JJ type_NN II_NNP collagen_NN ._. On_IN day_NN 21_CD
          after_IN priming_VBG ,_, mice_NNS received_VBD a_DT boost_NN injection_NN
          (_( intradermally_RB )_) with_IN 100_CD μ_NN g_SYM type_NN II_NNP collagen_NN in_IN
          incomplete_JJ adjuvant_NN ._. For_IN the_DT synchronous_JJ onset_NN of_IN
          arthritis_NN ,_, 40_CD μ_NN g_SYM lipopolysaccharide_NN (_( Sigma_NNP ,_, St_NNP Louis_NNP ,_,
          MO_NNP ,_, USA_NNP )_) was_VBD injected_VBN intraperitoneally_RB on_IN day_NN 28_CD ._.
          Ad-m_NNP IL-_NNP 4_CD was_VBD injected_VBN periarticularly_RB into_IN the_DT hind_NN ankle_NN
          joints_NNS of_IN mice_NNS on_IN day_NN 32_CD or_CC intravenously_RB by_IN tail_NN vein_NN
          injection_NN on_IN day_NN 29_CD ._. Disease_NN severity_NN was_VBD monitored_VBN every_DT
          other_JJ day_NN using_VBG an_DT established_VBN macroscopic_JJ scoring_VBG system_NN
          ranging_VBG from_IN 0_CD to_TO 4_CD :_: 0_CD ,_, normal_JJ ;_: 1_CD ,_, detectable_JJ arthritis_NN
          with_IN erythma_NN ;_: 2_CD ,_, significant_JJ swelling_VBG and_CC redness_NNS ;_: 3_CD ,_,
          severe_JJ swelling_VBG and_CC redness_NNS from_IN joint_JJ to_TO digit_NN ;_: and_CC 4_CD ,_,
          maximal_NN swelling_VBG with_IN ankylosis_NNS ._. The_DT average_NN of_IN
          macroscopic_JJ score_NN was_VBD expressed_VBN as_IN a_DT cumulative_JJ value_NN for_IN
          all_DT paws_NNS ,_, with_IN a_DT maximum_NN possible_JJ score_NN of_IN 16_CD per_IN mouse_NN ._.
          Cytokine_NNP production_NN by_IN joint_JJ tissue_NN or_CC serum_NN were_VBD
          assessed_VBN using_VBG enzyme-linked_JJ immunosorbent_NN assay_NN (_( ELISA_NNP ;_:
          R_NN &_CC D_NNP Systems_NNPS ,_, Minneapolis_NNP ,_, MN_NNP ,_, USA_NNP )_) ._.
        
        
          Results_NNS
          To_TO examine_VB the_DT therapeutic_JJ effects_NNS of_IN IL-_NNP 4_CD gene_NN
          transfer_NN in_IN a_DT murine_NN model_NN of_IN arthritis_NN ,_, 5_CD ×_NN 10_CD 8_CD particles_NNS
          of_IN Ad-m_NNP IL-_NNP 4_CD and_CC enhanced_VBN green_JJ fluorescent_NN protein_NN
          (_( Ad-e_NNP GFP_NNP )_) were_VBD administered_VBN by_IN periarticular_NN injection_NN
          into_IN the_DT ankle_NN joints_NNS of_IN mice_NNS with_IN established_VBN disease_NN 4_CD
          days_NNS after_IN lipopolysaccharide_NN injection_NN ._. All_DT mice_NNS had_VBD
          established_VBN disease_NN at_IN time_NN of_IN injection_NN ._. As_IN shown_VBN in_IN
          Figure_NN 1_CD ,_, the_DT severity_NN of_IN arthritis_NN (_( Fig_NNP ._. 1_LS a_DT )_) ,_, paw_NN
          thickness_NN (_( Fig_NNP ._. 1_LS b_SYM )_) ,_, and_CC the_DT number_NN of_IN arthritic_JJ paws_NNS
          (_( Fig_NNP ._. 1_LS c_SYM )_) were_VBD all_DT significantly_RB reduced_VBN in_IN the_DT Ad-m_NNP IL-_NNP 4_CD
          group_NN ,_, compared_VBN with_IN the_DT saline-_NN and_CC Ad-e_NNP GFP-treated_NNP
          groups_NNS ._. Analysis_NNP of_IN the_DT bones_NNS in_IN the_DT ankle_NN joints_NNS of_IN
          control_NN arthritic_JJ mice_NNS showed_VBD evidence_NN of_IN erosion_NN with_IN an_DT
          associated_VBN monocytic_JJ infiltrate_VB around_IN the_DT joint_JJ space_NN
          compared_VBN with_IN the_DT Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN and_CC nonarthritic_JJ
          control_NN joints_NNS ._. In_IN addition_NN ,_, injection_NN of_IN the_DT ankle_NN
          joints_NNS in_IN the_DT hind_NN legs_NNS resulted_VBD in_IN a_DT therapeutic_JJ effect_NN
          in_IN the_DT front_JJ paws_NNS ._. A_DT similar_JJ contralateral_NN effect_NN has_VBZ
          been_VBN observed_VBN with_IN adenoviral-mediated_JJ delivery_NN of_IN viral_JJ
          (_( v_NN )_) -_: IL-_NNP 10_CD ._. Interestingly_RB ,_, a_DT high_JJ level_NN of_IN murine_NN IL-_NNP 10_CD
          also_RB was_VBD detected_VBN from_IN the_DT joint_JJ lysates_NNS of_IN
          Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN naïve_NN and_CC arthritic_JJ mice_NNS ,_, with_IN the_DT
          production_NN of_IN endogenous_JJ IL-_NNP 10_CD correlating_VBG with_IN the_DT dose_NN
          of_IN Ad-m_NNP IL-_NNP 4_CD ._. The_DT administration_NN of_IN recombinant_JJ IL-_NNP 4_CD
          protein_NN systemically_RB has_VBZ been_VBN shown_VBN to_TO be_VB therapeutic_JJ in_IN
          murine_NN CIA_NNP models_NNS if_IN given_VBN before_IN disease_NN onset_NN ._. To_TO
          examine_VB the_DT effect_NN of_IN systemic_JJ IL-_NNP 4_CD delivered_VBN by_IN gene_NN
          transfer_NN ,_, 1_CD ×_NN 10_CD 9_CD particles_NNS of_IN Ad-m_NNP IL-_NNP 4_CD were_VBD injected_VBN via_IN
          the_DT tail_NN vein_NN of_IN collagen-immunized_JJ mice_NNS the_DT day_NN after_IN
          lipopolysaccharide_NN injection_NN ._. Whereas_IN the_DT immunized_JJ
          control_NN mice_NNS ,_, injected_VBN with_IN Ad-e_NNP GFP_NNP ,_, showed_VBD disease_NN onset_NN
          on_IN day_NN 3_CD after_IN lipopolysaccharide_NN injection_NN ,_,
          Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN mice_NNS showed_VBD a_DT delay_NN in_IN disease_NN onset_NN and_CC
          as_IN a_DT reduction_NN in_IN the_DT total_JJ number_NN of_IN arthritic_JJ paws_NNS ._.
          Also_RB ,_, systemic_JJ injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD suppressed_VBD the_DT
          severity_NN of_IN arthritis_NN in_IN CIA_NNP mice_NNS according_VBG to_TO arthritis_NN
          index_NN ._.
        
        
          Discussion_NNP
          Gene_NNP therapy_NN represents_VBZ a_DT novel_NN approach_NN for_IN delivery_NN
          of_IN therapeutic_JJ agents_NNS to_TO joints_NNS in_IN order_NN to_TO treat_VB the_DT
          pathologies_NNS associated_VBN with_IN RA_NNP and_CC osteoarthritis_NNS ,_, as_RB
          well_RB as_IN other_JJ disorders_NNS of_IN the_DT joints_NNS ._. In_IN the_DT present_JJ
          study_NN we_PRP examined_VBD the_DT ability_NN of_IN local_JJ periarticular_NN and_CC
          systemic_JJ gene_NN transfer_NN of_IN IL-_NNP 4_CD to_TO treat_VB established_VBN and_CC
          early-stage_JJ murine_NN CIA_NNP ,_, respectively_RB ._. We_PRP have_VBP
          demonstrated_VBN that_IN both_DT local_JJ and_CC systemic_JJ administration_NN
          of_IN Ad-m_NNP IL-_NNP 4_CD resulted_VBD in_IN a_DT reduction_NN in_IN the_DT severity_NN of_IN
          arthritis_NN ,_, as_RB well_RB as_IN in_IN the_DT number_NN of_IN arthritic_JJ paws_NNS ._. In_IN
          addition_NN ,_, the_DT local_JJ gene_NN transfer_NN of_IN IL-_NNP 4_CD reduced_VBN
          histologic_JJ signs_NNS of_IN inflammation_NN and_CC of_IN bone_NN erosion_NN ._.
          Interestingly_RB ,_, local_JJ delivery_NN of_IN Ad-m_NNP IL-_NNP 4_CD was_VBD able_JJ to_TO
          confer_VB a_DT therapeutic_JJ effect_NN to_TO the_DT untreated_JJ ,_, front_JJ paws_NNS
          through_IN a_DT currently_RB unknown_JJ mechanism_NN ._. In_IN addition_NN ,_, both_DT
          local_JJ and_CC systemic_JJ expression_NN of_IN IL-_NNP 4_CD resulted_VBD in_IN an_DT
          increase_NN in_IN the_DT level_NN of_IN endogenous_JJ IL-_NNP 10_CD ,_, as_RB well_RB as_IN of_IN
          IL-_NNP 1_CD Ra_NNP (_( data_NNS not_RB shown_VBN )_) ._. Previous_JJ experiments_NNS have_VBP shown_VBN
          that_DT gene_NN transfer_NN of_IN IL-_NNP 10_CD and_CC IL-_NNP 1_CD and_CC TNF_NNP inhibitors_NNS
          at_IN the_DT time_NN of_IN disease_NN initiation_NN (_( day_NN 28_CD )_) is_VBZ
          therapeutic_JJ ._. However_RB ,_, delivery_NN of_IN these_DT agents_NNS after_IN

          disease_NN onset_NN appeared_VBD to_TO have_VB only_RB limited_JJ therapeutic_JJ
          effect_NN ._. In_IN contrast_NN ,_, the_DT present_JJ results_NNS demonstrate_VBP that_IN
          IL-_NNP 4_CD ,_, resulting_VBG from_IN local_JJ periarticular_NN and_CC systemic_JJ
          injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD ,_, was_VBD able_JJ partially_RB to_TO reverse_VB
          progression_NN of_IN established_VBN and_CC early-stage_JJ disease_NN ,_,
          respectively_RB ._. These_DT results_NNS ,_, as_RB well_RB as_IN those_DT of_IN others_NNS ,_,
          support_NN the_DT potential_JJ application_NN of_IN IL-_NNP 4_CD gene_NN therapy_NN
          for_IN the_DT clinical_JJ treatment_NN of_IN RA_NNP ._.
        
      
      
        Introduction_NNP
        RA_NNP is_VBZ a_DT chronic_JJ systemic_JJ autoimmune_JJ disease_NN that_WDT is_VBZ
        characterized_VBN by_IN joint_JJ inflammation_NN ,_, and_CC progressive_JJ
        cartilage_NN and_CC bone_NN erosion_NN ._. Currently_RB the_DT symptoms_NNS of_IN
        arthritis_NN are_VBP managed_VBN using_VBG pharmacologic_JJ agents_NNS ,_, including_VBG
        both_DT steroidal_NN and_CC nonsteroidal_NN drugs_NNS ,_, and_CC
        disease-modifying_JJ drugs_NNS such_JJ as_IN methotrexate_NN ._. No_DT
        pharmacologic_JJ agents_NNS have_VBP yet_RB proven_VBN effective_JJ in_IN halting_VBG
        the_DT progression_NN of_IN disease_NN ,_, however_RB ._. Recent_JJ research_NN has_VBZ
        identified_VBN certain_JJ biologic_JJ agents_NNS that_WDT appear_VBP more_RBR able_JJ
        than_IN conventional_JJ therapies_NNS to_TO halt_VB effectively_RB the_DT
        progression_NN of_IN disease_NN ,_, as_RB well_RB as_IN ameliorate_NN disease_NN
        symptoms_NNS ._. In_IN particular_JJ ,_, inhibitors_NNS of_IN TNF-α_NNP and_CC IL-_NNP 1_CD have_VBP
        proven_VBN effective_JJ in_IN clinical_JJ trials_NNS ,_, and_CC the_DT US_NNP Food_NNP and_CC
        Drug_NNP Administration_NNP has_VBZ approved_VBN the_DT use_NN of_IN soluble_JJ TNF-α_NNP
        receptor_NN for_IN treatment_NN of_IN human_JJ RA_NNP ._. One_CD potential_JJ problem_NN
        with_IN the_DT use_NN of_IN biologic_JJ agents_NNS for_IN arthritis_NN therapy_NN is_VBZ
        the_DT need_NN for_IN daily_JJ or_CC weekly_JJ repeat_NN dosing_VBG ._. The_DT transfer_NN of_IN
        genes_NNS directly_RB to_TO the_DT synovial_NN lining_NN can_MD theoretically_RB
        circumvent_VB the_DT need_NN for_IN repeat_NN dosing_VBG and_CC reduce_VB potential_JJ
        systemic_JJ side_NN effects_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. Ex-vivo_NNP and_CC in-vivo_JJ methods_NNS
        have_VBP been_VBN used_VBN to_TO deliver_VB therapeutic_JJ genes_NNS such_JJ as_IN those_DT
        that_DT encode_NN IL-_NNP 10_CD ,_, v-_NN IL-_NNP 10_CD ,_, soluble_JJ TNF_NNP and_CC IL-_NNP 1_CD receptors_NNS ,_,
        and_CC IL-_NNP 1_CD Ra_NNP to_TO arthritic_JJ mouse_NN [_NN 10_CD ]_NN ,_, rat_NN [_NN 11_CD ]_NN ,_, dog_NN [_NN 12_CD ]_NN ,_,
        and_CC rabbit_NN joints_NNS [_NN 13_CD ]_NN ._. Although_IN many_JJ genes_NNS have_VBP been_VBN
        effective_JJ in_IN treating_VBG murine_NN CIA_NNP if_IN they_PRP are_VBP administered_VBN
        before_IN disease_NN onset_NN ,_, local_JJ periarticular_NN gene_NN transfer_NN has_VBZ
        not_RB been_VBN highly_RB effective_JJ in_IN halting_VBG the_DT progression_NN of_IN
        established_VBN disease_NN ._.
        IL-_NNP 4_CD ,_, similar_JJ to_TO TNF-α_NNP and_CC IL-_NNP 1_CD inhibitors_NNS ,_, has_VBZ been_VBN
        shown_VBN be_VB therapeutic_JJ for_IN the_DT treatment_NN of_IN murine_NN CIA_NNP when_WRB
        administered_VBN intravenously_RB as_IN a_DT recombinant_JJ protein_NN ,_, either_CC
        alone_RB or_CC in_IN combination_NN with_IN IL-_NNP 10_CD ._. IL-_NNP 4_CD can_MD down-regulate_JJ
        the_DT production_NN of_IN proinflammatory_NN and_CC Th_NNP 1_CD -_: type_NN cytokines_NNS by_IN
        inducing_VBG mRNA_NN degradation_NN and_CC upregulating_VBG the_DT expression_NN
        of_IN inhibitors_NNS of_IN proinflammatory_NN cytokines_NNS such_JJ as_IN IL-_NNP 1_CD Ra_NNP [_NN
        3_CD ,_, 4_CD ]_NN ._. IL-_NNP 4_CD is_VBZ able_JJ to_TO inhibit_VB IL-_NNP 2_CD and_CC IFN-γ_NNP production_NN by_IN
        Th_NNP 1_CD cells_NNS ,_, resulting_VBG in_IN suppression_NN of_IN macrophage_NN
        activation_NN and_CC the_DT production_NN of_IN the_DT proinflammatory_NN
        cytokines_NNS IL-_NNP 1_CD ,_, IL-_NNP 6_CD ,_, IL-_NNP 8_CD ,_, and_CC TNF-α_NNP by_IN monocytes_NNS and_CC
        macrophages_NNS [_NN 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. In_IN addition_NN ,_, IL-_NNP 4_CD inhibits_NNS
        growth_NN factor-induced_JJ RA_NNP synoviocyte_NN proliferation_NN ,_, and_CC
        expression_NN of_IN prostaglandin_NN E_NNP and_CC matrix_NN
        metalloproteinase-_NN 3_CD in_IN RA_NNP synovial_NN fibroblast_NN [_NN 14_CD ,_, 15_CD ,_,
        16_CD ]_NN ,_, and_CC reduces_VBZ bone_NN resorption_NN ._. Given_VBN that_IN IL-_NNP 4_CD is_VBZ able_JJ
        to_TO inhibit_VB the_DT production_NN of_IN both_DT IL-_NNP 1_CD and_CC TNF-α_NNP ,_, block_VB
        synovial_NN cell_NN proliferation_NN and_CC bone_NN loss_NN ,_, and_CC promote_VB the_DT
        formation_NN of_IN Th_NNP 2_CD lymphocytes_NNS ,_, it_PRP represents_VBZ an_DT attractive_JJ
        cytokine_NN for_IN treating_VBG arthritis_NN by_IN gene_NN transfer_NN ._.
        To_TO examine_VB the_DT therapeutic_JJ effects_NNS of_IN local_JJ and_CC systemic_JJ
        IL-_NNP 4_CD expression_NN in_IN established_VBN CIA_NNP ,_, we_PRP have_VBP generated_VBN an_DT
        adenoviral_NN vector_NN carrying_VBG the_DT gene_NN for_IN murine_NN IL-_NNP 4_CD
        (_( Ad-m_NNP IL-_NNP 4_LS )_) ._. The_DT ability_NN of_IN Ad-m_NNP IL-_NNP 4_CD to_TO treat_VB established_VBN
        CIA_NNP was_VBD evaluated_VBN by_IN local_JJ periarticular_NN and_CC systemic_JJ
        intravenous_JJ injections_NNS of_IN Ad-m_NNP IL-_NNP 4_CD into_IN mice_NNS at_IN various_JJ
        times_NNS after_IN disease_NN onset_NN ._. Local_JJ injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD
        resulted_VBD in_IN a_DT reduction_NN in_IN the_DT severity_NN of_IN arthritis_NN and_CC
        joint_NN swelling_VBG ,_, and_CC reduced_VBD macroscopic_JJ signs_NNS of_IN joint_JJ
        inflammation_NN and_CC bone_NN erosion_NN ._. Injection_NNP of_IN the_DT ankle_NN
        joints_NNS in_IN the_DT hind_NN legs_NNS also_RB resulted_VBD in_IN a_DT therapeutic_JJ
        effect_NN in_IN the_DT untreated_JJ ,_, front_JJ paws_NNS ._. A_DT high_JJ level_NN of_IN
        endogenous_JJ murine_NN IL-_NNP 10_CD was_VBD detected_VBN in_IN the_DT joint_JJ tissues_NNS
        of_IN mice_NNS injected_VBN locally_RB with_IN Ad-m_NNP IL-_NNP 4_CD ._. Systemic_NNP delivery_NN
        of_IN murine_NN IL-_NNP 4_CD by_IN intravenous_JJ injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD also_RB
        resulted_VBD in_IN a_DT slight_JJ delay_NN in_IN the_DT onset_NN of_IN disease_NN ,_, with_IN a_DT
        significant_JJ reduction_NN in_IN the_DT number_NN of_IN arthritic_JJ paws_NNS ._.
        These_DT results_NNS demonstrate_VBP that_IN local_JJ and_CC systemic_JJ gene_NN
        transfer_NN of_IN IL-_NNP 4_CD is_VBZ able_JJ to_TO treat_VB established_VBN and_CC
        early-stage_JJ disease_NN ,_, respectively_RB ,_, in_IN a_DT mouse_NN model_NN of_IN
        arthritis_NN ,_, and_CC thus_RB may_MD be_VB useful_JJ for_IN clinical_JJ applications_NNS
        for_IN the_DT treatment_NN of_IN RA_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          Male_NNP DBA_NNP /_NN 1_CD lacJ_NN (_( H-_NNP 2_CD 
          q_NN )_) mice_NNS ,_, aged_VBN 7_CD -_: 8_CD weeks_NNS ,_, were_VBD
          purchased_VBN from_IN The_DT Jackson_NNP Laboratory_NNP ._. They_PRP were_VBD
          maintained_VBN in_IN a_DT specific_JJ pathogen-free_JJ animal_NN facility_NN of_IN
          the_DT University_NNP of_IN Pittsburgh_NNP Biotechnology_NNP Center_NNP ._. For_IN
          local_JJ periarticular_NN injection_NN ,_, mice_NNS were_VBD anesthetized_JJ
          with_IN inhalation_NN of_IN 2_CD ._. 5_CD %_NN isoflurane_NN gas_NN ._. A_DT maximum_NN of_IN 5_CD μ_NN
          l_NN diluted_VBD adenovirus_JJ was_VBD injected_VBN into_IN joint_JJ articular_NN
          space_NN under_IN the_DT ankle_NN joint_JJ bone_NN in_IN each_DT hind_NN paw_NN with_IN a_DT
          26_CD -_: gauge_VB Hamilton_NNP syringe_NN ._. For_IN systemic_JJ delivery_NN of_IN
          adenovirus_JJ ,_, 500_CD μ_NN l_NN diluted_VBD adenovirus_JJ was_VBD injected_VBN
          intravenously_RB via_IN the_DT tail_NN vein_NN ._.
        
        
          Vector_NNP construction_NN and_CC adenovirus_JJ
          generation_NN
          Ad-m_NNP IL-_NNP 4_CD was_VBD constructed_VBN and_CC propagated_JJ according_VBG to_TO
          standard_JJ protocols_NNS ,_, as_RB previously_RB described_VBD [_NN 17_CD ]_NN ._.
          Briefly_NNP ,_, recombinant_JJ adenoviruses_NNS were_VBD generated_VBN by_IN
          homologous_RB recombination_NN in_IN CRE_NNP 8_CD cells_NNS ,_, a_DT 293_CD cell_NN line_NN
          that_WDT expresses_VBZ Cre_NNP recombinase_NN ,_, between_IN psi-_NN 5_CD ,_, an_DT
          Ad_NN 5_CD -_: derived_VBN ,_, E_NNP 1_CD -_: and_CC E_NNP 3_CD -_: deleted_VBN adenovirus_JJ ,_, and_CC pAd-lox_JJ ,_,
          the_DT adenoviral_NN shuttle_NN vector_NN that_WDT expresses_VBZ IL-_NNP 4_CD ._. The_DT
          inserted_VBN cDNA_NN sequences_NNS are_VBP expressed_VBN under_IN the_DT
          transcriptional_NN control_NN of_IN human_JJ cytomegalovirus_JJ
          promoter_NN ._.
          Vectors_NNP were_VBD purified_JJ using_VBG two_CD consecutive_JJ CsCl_NNP
          gradient_NN ultracentrifugation_NN ,_, dialyzed_JJ at_IN 4_CD °_NN C_NNP against_IN
          sterile_JJ virus_NN buffer_NN ,_, aliquoted_JJ ,_, and_CC stored_VBD at_IN -_: 80_CD °_NN C_NNP
          until_IN use_NN ._. The_DT titers_NNS of_IN the_DT adenoviral_NN stocks_NNS were_VBD
          determined_VBN by_IN incubating_VBG serial_NN dilutions_NNS of_IN the_DT stocks_NNS
          at_IN 37_CD °_NN C_NNP for_IN 60_CD min_NN with_IN sub-confluent_JJ 293_CD cells_NNS ._. Viral_NNP
          titers_NNS were_VBD calculated_VBN by_IN determining_VBG the_DT highest_JJS
          dilution_NN that_WDT produced_VBD 100_CD %_NN viral_JJ cytopathic_JJ effect_NN ,_,
          which_WDT was_VBD then_RB multiplied_VBN by_IN the_DT number_NN of_IN cells_NNS per_IN well_RB
          and_CC by_IN the_DT dilution_NN factor_NN ._. CRE_NNP 8_CD and_CC 293_CD cell_NN lines_NNS were_VBD
          grown_VBN in_IN Dulbecco_NNP 's_POS modified_VBN eagle_NN medium_NN (_( GIBCO-BRL_NNP ,_,
          Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN ._.
        
        
          Induction_NNP of_IN arthritis_NN
          Bovine_NNP typeII_NN collagen_NN (_( Chondrex_NNP ,_, Seattle_NNP ,_, WA_NNP ,_, USA_NNP )_)
          was_VBD dissolved_VBN in_IN 0_CD ._. 05_CD mol_NN /_NN l_NN acetic_JJ acid_NN at_IN a_DT concentration_NN
          of_IN 2_CD mg_NN /_NN ml_NN by_IN stirring_VBG overnight_JJ at_IN 4_CD °_NN C_NNP and_CC emulsified_JJ in_IN
          equal_JJ volumes_NNS of_IN FCA_NNP containing_VBG 2_CD mg_NN /_NN ml_NN heat-killed_JJ 
          Mycobacterium_NNP tuberculosis_NNS strain_VBP
          H_NNP 37_CD Ra_NNP ._. The_DT mice_NNS were_VBD immunized_JJ intradermally_RB at_IN the_DT base_NN
          of_IN tail_NN with_IN 100_CD μ_NN g_SYM collagen_NN ._. On_IN day_NN 21_CD after_IN priming_VBG ,_,
          the_DT mice_NNS were_VBD boosted_VBN with_IN 100_CD μ_NN g_SYM type_NN II_NNP collagen_NN in_IN
          incomplete_JJ adjuvant_NN ._. In_IN order_NN to_TO synchronize_VBP the_DT onset_NN of_IN
          arthritis_NN ,_, 40_CD μ_NN g_SYM lipopolysaccharide_NN (_( Sigma_NNP )_) was_VBD injected_VBN
          intraperitoneally_RB on_IN day_NN 28_CD ._.
        
        
          Disease_NN evaluation_NN
          Disease_NN severity_NN was_VBD assessed_VBN every_DT other_JJ day_NN using_VBG an_DT
          established_VBN macroscopic_JJ scoring_VBG system_NN ranging_VBG from_IN 0_CD to_TO
          4_CD :_: 0_CD ,_, normal_JJ ;_: 1_CD ,_, detectable_JJ arthritis_NN with_IN erythma_NN ;_: 2_CD ,_,
          significant_JJ swelling_VBG and_CC redness_NNS ;_: 3_CD ,_, severe_JJ swelling_VBG and_CC
          redness_NNS from_IN joint_JJ to_TO digit_NN ;_: and_CC 4_CD ,_, maximal_NN swelling_VBG with_IN
          ankylosis_NNS ._. The_DT macroscopic_JJ score_NN (_( mean_VB ±_NN standard_JJ
          deviation_NN )_) was_VBD expressed_VBN as_IN a_DT cumulative_JJ value_NN for_IN all_DT
          paws_NNS ,_, with_IN a_DT maximum_NN possible_JJ score_NN of_IN 16_CD ._. The_DT thickness_NN
          of_IN each_DT paw_NN was_VBD also_RB measured_VBN using_VBG a_DT spring-load_JJ
          caliper_NN ._. The_DT paw_NN swelling_VBG for_IN each_DT mouse_NN was_VBD calculated_VBN
          by_IN adding_VBG the_DT four_CD thicknesses_NNS of_IN the_DT individual_JJ paws_NNS ._. In_IN
          addition_NN ,_, the_DT number_NN of_IN arthritic_JJ paws_NNS of_IN individual_JJ mice_NNS
          were_VBD counted_VBN and_CC added_VBN to_TO represent_VB the_DT number_NN of_IN
          arthritic_JJ paws_NNS in_IN a_DT group_NN ._. The_DT 
          in_IN vivo_NN experiments_NNS were_VBD performed_VBN
          with_IN 10_CD mice_NNS /_NN group_NN and_CC repeated_VBN three_CD times_NNS to_TO ensure_VB
          reproducibility_NN ._.
        
        
          Histologic_NNP examination_NN
          Joint_NNP tissues_NNS from_IN freshly_RB dissected_VBN mice_NNS were_VBD
          immersion-fixed_JJ in_IN 10_CD %_NN neutral_JJ buffered_JJ formalin_NN and_CC
          decalcified_JJ in_IN 15_CD %_NN ethylene_NN diamine_NN tetra-acetic_JJ acid_NN /_NN 30_CD %_NN
          glycerol_NN for_IN 2_CD weeks_NNS ._. Tissues_NNPS were_VBD then_RB dehydrated_JJ in_IN
          graded_JJ alcohols_NNS ,_, embedded_VBN in_IN paraplast_NN ,_, sectioned_JJ at_IN 5_CD μ_NN m_NN
          on_IN a_DT microtome_NN ,_, and_CC stained_JJ with_IN hematoxylin_NN and_CC eosin_NN ._.
          Sections_NNP were_VBD evaluated_VBN in_IN a_DT blinded_JJ manner_NN for_IN
          histologic_JJ signs_NNS of_IN arthritis_NN and_CC scored_VBD as_IN follows_VBZ :_: 1_CD ,_,
          synovial_NN cell_NN proliferation_NN ,_, synovial_NN hypertrophy_NN with_IN
          villus_JJ formation_NN and_CC /_NN or_CC fibrin_NN deposition_NN ;_: 2_CD ,_,
          inflammation_NN ,_, synovitis_NNS and_CC /_NN or_CC generalized_JJ inflammation_NN ;_:
          3_CD ,_, cartilage_NN disruption_NN ,_, chondrocyte_NN degeneration_NN and_CC /_NN or_CC
          ruffling_VBG of_IN cartilage_NN surface_NN and_CC /_NN or_CC dystrophic_JJ
          cartilage_NN ;_: and_CC 4_CD ,_, joint_JJ destruction_NN ,_, cartilage_NN erosion_NN
          with_IN abundant_JJ inflammation_NN and_CC pannus_JJ formation_NN with_IN bone_NN
          erosion_NN ._.
        
        
          Type_NNP II_NNP collagen_NN antibody_NN titration_NN
          Serum_NNP level_NN of_IN antibody_NN against_IN type_NN II_NNP collagen_NN was_VBD
          measured_VBN using_VBG a_DT standard_JJ ELISA_NNP assay_NN ._. Briefly_NNP ,_, a_DT 96_CD -_: well_RB
          Immuno-_NNP Maxisorp_NNP Plate_NNP (_( Nunc_NNP ,_, Naperville_NNP ,_, IL_NNP ,_, USA_NNP )_) was_VBD
          coated_VBN with_IN bovine_JJ type_NN II_NNP collagen_NN (_( 10_CD μ_NN g_SYM /_NN ml_NN )_) overnight_JJ
          at_IN 4_CD °_NN C_NNP and_CC blocked_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN in_IN
          phosphate-buffered_JJ saline_NN ._. Sample_NNP sera_NN were_VBD diluted_VBN to_TO
          1_CD :_: 100000_CD (_( vol_NN :_: vol_NN )_) and_CC incubated_JJ for_IN 2_CD h_NN at_IN 37_CD °_NN C_NNP ._. After_IN
          washing_VBG ,_, bound_VBN antibody_NN isotope_NN was_VBD detected_VBN with_IN
          biotin-conjugated_JJ antimouse_NN whole_JJ IgG_NNP (_( heavy_JJ and_CC light_JJ
          chain_NN )_) antibody_NN (_( Pharmingen_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
          Thereafter_RB ,_, plates_NNS were_VBD washed_VBN ,_, incubated_JJ with_IN 100_CD μ_NN l_NN
          2_CD ,_, 2_CD -_: azino-di-_JJ (_( -_: 3_CD -_: ethyl-benzthiazolinesulfonate_JJ )_) substrate_NN
          (_( ABTS_NNP ;_: Boeringer_NNP Mannheim_NNP ,_, Indianapolis_NNP ,_, IN_IN ,_, USA_NNP )_) at_IN
          1_CD mg_NN /_NN ml_NN and_CC read_VB at_IN 405_CD nm_NN ._.
        
        
          Cytokine_NNP production_NN
          Cytokine_NNP production_NN in_IN the_DT joint_JJ tissue_NN or_CC serum_NN was_VBD
          assessed_VBN by_IN ELISA_NNP (_( R_NN &_CC D_NNP systems_NNS )_) ._. For_IN measuring_VBG the_DT
          cytokine_NN production_NN ,_, peeled_VBN joint_JJ tissues_NNS from_IN the_DT upper_JJ
          portion_NN of_IN ankle_NN to_TO the_DT middle_NN of_IN the_DT paw_NN were_VBD ground_VBN by_IN
          homogenizer_NN in_IN the_DT equal_JJ volume_NN of_IN the_DT lysis_NNS buffer_NN
          (_( 100_CD mmol_NN /_NN l_NN potassuim_NN phosphate_NN ,_, pH_NN 7_CD ._. 8_CD and_CC 0_CD ._. 2_CD %_NN Triton-_NNP X_NNP
          100_CD )_) ._. Cytokine_NNP production_NN was_VBD standardized_JJ as_IN amount_NN of_IN
          cytokine_NN per_IN gram_NN of_IN tissue_NN ._.
        
        
          Statistical_NNP analysis_NN
          Results_NNS were_VBD compared_VBN using_VBG the_DT Student_NNP 's_POS 
          t_NN -_: test_NN and_CC by_IN analysis_NN of_IN
          variance_NN ._. 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        
          Local_JJ delivery_NN of_IN Ad-m_NNP IL-_NNP 4_CD in_IN established_VBN CIA_NNP mouse_NN
          model_NN
          To_TO establish_VB CIA_NNP ,_, 8_CD -_: week-old_JJ aged_VBN DBA_NNP 1_CD /_NN lacJ_NN male_JJ mice_NNS
          were_VBD immunized_JJ with_IN 100_CD μ_NN g_SYM bovine_JJ type_NN II_NNP collagen_NN
          emulsified_JJ in_IN complete_JJ adjuvant_NN ._. After_IN 21_CD days_NNS ,_, the_DT mice_NNS
          were_VBD boosted_VBN with_IN the_DT same_JJ amount_NN of_IN collagen_NN in_IN
          incomplete_JJ adjuvant_NN ,_, with_IN disease_NN pathology_NN observed_VBD
          starting_VBG 28_CD days_NNS after_IN immunization_NN ._. In_IN order_NN to_TO
          synchronize_VBP the_DT onset_NN of_IN arthritis_NN ,_, lipopolysaccharide_NN
          was_VBD injected_VBN intraperitoneally_RB on_IN day_NN 28_CD ,_, excluding_VBG the_DT
          mice_NNS that_WDT had_VBD already_RB showed_VBN signs_NNS of_IN disease_NN pathology_NN ._.
          All_DT of_IN the_DT collagen-immunized_JJ mice_NNS had_VBD swollen_JJ and_CC red_JJ
          paws_NNS and_CC ankle_NN joints_NNS within_IN 3_CD days_NNS after_IN
          lipopolysaccharide_NN injection_NN ._.
          In_IN order_NN to_TO examine_VB the_DT therapeutic_JJ effects_NNS of_IN IL-_NNP 4_CD
          gene_NN transfer_NN in_IN a_DT murine_NN model_NN of_IN arthritis_NN ,_, increasing_VBG
          doses_NNS of_IN an_DT Ad-m_NNP IL-_NNP 4_CD recombinant_JJ virus_NN were_VBD administered_VBN
          by_IN periarticular_NN injection_NN into_IN the_DT hind_NN ankle_NN joints_NNS of_IN
          mice_NNS with_IN established_VBN disease_NN 4_CD days_NNS after_IN
          lipopolysaccharide_NN injection_NN ._.
          As_IN shown_VBN in_IN Figure_NN 1_CD ,_, all_DT mice_NNS had_VBD established_VBN disease_NN
          at_IN time_NN of_IN injection_NN ._. However_RB ,_, the_DT severity_NN of_IN arthritis_NN
          (_( Fig_NNP ._. 1_LS a_DT )_) ,_, paw_NN thickness_NN (_( Fig_NNP ._. 1_LS b_SYM )_) ,_, and_CC the_DT number_NN of_IN
          arthritic_JJ paws_NNS (_( Fig_NNP ._. 1_LS c_SYM )_) were_VBD all_DT significantly_RB reduced_VBN
          in_IN the_DT Ad-m_NNP IL-_NNP 4_CD group_NN ,_, compared_VBN with_IN the_DT saline-_NN and_CC
          Ad-e_NNP GFP-treated_NNP groups_NNS ._.
          Analysis_NNP of_IN the_DT bones_NNS in_IN the_DT ankle_NN joints_NNS of_IN control_NN
          arthritic_JJ mice_NNS showed_VBD evidence_NN of_IN erosion_NN with_IN an_DT
          associated_VBN monocytic_JJ infiltrate_VB around_IN the_DT joint_JJ space_NN
          (_( Fig_NNP ._. 2_LS a_DT )_) compared_VBN with_IN the_DT nonarthritic_JJ control_NN joints_NNS ._.
          In_IN contrast_NN ,_, the_DT joints_NNS from_IN Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN mice_NNS showed_VBD
          less_RBR inflammatory_JJ joint_JJ tissue_NN ,_, reduction_NN in_IN bone_NN
          erosion_NN ,_, and_CC reduction_NN in_IN the_DT number_NN of_IN inflammatory_JJ
          cells_NNS ._. The_DT changes_NNS in_IN histology_NN of_IN the_DT ankle_NN joints_NNS from_IN
          sections_NNS from_IN five_CD mice_NNS per_IN group_NN were_VBD also_RB scored_VBN in_IN a_DT
          blinded_JJ manner_NN ._. As_IN shown_VBN in_IN Figure_NN 2_CD b_SYM ,_, significant_JJ
          inhibition_NN of_IN disease_NN progression_NN as_IN assessed_VBN by_IN joint_JJ
          histology_NN was_VBD observed_VBN in_IN the_DT Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN group_NN ._.
          These_DT results_NNS suggest_VBP that_IN local_JJ expression_NN of_IN IL-_NNP 4_CD
          after_IN gene_NN transfer_NN to_TO joints_NNS with_IN established_VBN disease_NN
          could_MD effectively_RB protect_VB tissue_NN from_IN inflammation_NN as_RB
          well_RB as_IN block_NN bone_NN erosion_NN ._. It_PRP is_VBZ important_JJ to_TO note_VB that_IN
          the_DT possible_JJ inflammatory_JJ responses_NNS to_TO adenoviral_NN
          injection_NN were_VBD examined_VBN by_IN injection_NN of_IN the_DT same_JJ number_NN
          of_IN particles_NNS of_IN Ad-m_NNP IL-_NNP 4_CD and_CC Ad-e_NNP GFP_NNP into_IN naïve_NN joints_NNS of_IN
          DBA_NNP mice_NNS ._. At_IN the_DT doses_NNS of_IN virus_NN used_VBD ,_, however_RB ,_, no_DT
          inflammation_NN was_VBD observed_VBN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Reduction_NNP in_IN disease_NN severity_NN in_IN noninjected_JJ front_JJ
          paws_NNS by_IN local_JJ injection_NN of_IN IL-_NNP 4_CD
          Previously_RB ,_, we_PRP have_VBP noted_VBN a_DT contralateral_NN effect_NN ,_, in_IN
          which_WDT treatment_NN of_IN a_DT diseased_JJ joint_NN by_IN
          adenovirus-mediated_JJ transfer_NN of_IN the_DT gene_NN that_IN encodes_NNS
          v-_NN IL-_NNP 10_CD resulted_VBD in_IN a_DT therapeutic_JJ effect_NN in_IN noninjected_JJ
          joints_NNS ._. To_TO determine_VB whether_IN Ad-m_NNP IL-_NNP 4_CD was_VBD able_JJ to_TO confer_VB
          a_DT contralateral_NN effect_NN ,_, the_DT severity_NN of_IN disease_NN in_IN the_DT
          hind_NN and_CC front_JJ paws_NNS of_IN the_DT mice_NNS injected_VBN only_RB in_IN the_DT hind_NN
          ankle_NN joints_NNS was_VBD evaluated_VBN ._. As_IN shown_VBN in_IN Figure_NN 3_CD a_DT ,_, a_DT
          reduction_NN in_IN the_DT arthritis_NN index_NN was_VBD observed_VBN in_IN the_DT
          Ad-m_NNP IL-_NNP 4_CD injected_VBN hind_NN leg_NN ankle_NN joints_NNS of_IN the_DT CIA_NNP mice_NNS ._.
          Interestingly_RB ,_, the_DT noninjected_JJ front_JJ paws_NNS also_RB showed_VBD a_DT
          statistically_RB significant_JJ reduction_NN in_IN the_DT severity_NN of_IN
          arthritis_NN (_( Fig_NNP ._. 3_LS b_SYM )_) ._. Taken_VBN together_RB ,_, these_DT results_NNS
          suggest_VBP that_IN local_JJ periarticular_NN injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD
          resulted_VBD in_IN a_DT therapeutic_JJ effect_NN in_IN both_DT injected_VBN and_CC
          noninjected_JJ joints_NNS ._. However_RB ,_, unlike_IN v-_NN IL-_NNP 10_CD ,_, IL-_NNP 4_CD is_VBZ able_JJ
          to_TO confer_VB a_DT contralateral_NN therapeutic_JJ effect_NN in_IN mice_NNS with_IN
          established_VBN disease_NN ._.
        
        
          Stimulation_NNP of_IN endogenous_JJ IL-_NNP 10_CD expression_NN by_IN local_JJ
          IL-_NNP 4_CD gene_NN delivery_NN
          To_TO test_VB the_DT level_NN and_CC duration_NN of_IN gene_NN expression_NN ,_,
          5_CD ×_NN 10_CD 8_CD particles_NNS of_IN Ad-m_NNP IL-_NNP 4_CD ,_, Ad-m_NNP IL-_NNP 10_CD ,_, and_CC Ad-e_NNP GFP_NNP were_VBD
          injected_VBN periarticularly_RB into_IN the_DT ankle_NN joints_NNS of_IN naïve_NN
          DBA_NNP 1_CD mice_NNS ._. Joint_NNP tissues_NNS were_VBD isolated_VBN at_IN indicated_JJ time_NN
          points_NNS ,_, homogenized_JJ in_IN lysis_NNS buffer_NN ,_, and_CC the_DT lysates_NNS
          analyzed_VBD for_IN cytokine_NN production_NN by_IN ELISA_NNP ._. Maximal_NNP IL-_NNP 4_CD
          expression_NN was_VBD detected_VBN on_IN day_NN 7_CD ,_, with_IN the_DT level_NN
          gradually_RB decreasing_VBG over_IN time_NN (_( Fig_NNP ._. 4_LS a_DT )_) ._. However_RB ,_, it_PRP is_VBZ
          important_JJ to_TO note_VB that_IN it_PRP is_VBZ unclear_JJ whether_IN the_DT level_NN of_IN
          IL-_NNP 4_CD detected_VBD in_IN the_DT joints_NNS at_IN the_DT different_JJ time_NN points_NNS
          is_VBZ partially_RB due_JJ to_TO induction_NN of_IN endogenous_JJ IL-_NNP 4_CD ._.
          Interestingly_RB ,_, a_DT high_JJ level_NN of_IN murine_NN IL-_NNP 10_CD also_RB was_VBD
          detected_VBN from_IN the_DT joint_JJ lysates_NNS of_IN Ad-m_NNP IL-_NNP 4_CD -_: injected_VBN
          animals_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) that_IN directly_RB correlated_JJ with_IN the_DT dose_NN
          of_IN Ad-m_NNP IL-_NNP 4_CD (_( data_NNS not_RB shown_VBN )_) ._. An_DT increase_NN in_IN the_DT level_NN of_IN
          IL-_NNP 10_CD expression_NN could_MD even_RB be_VB detected_VBN 3_CD weeks_NNS after_IN
          injection_NN of_IN a_DT high_JJ dose_NN of_IN Ad-m_NNP IL-_NNP 4_CD ._.
          The_DT levels_NNS of_IN IL-_NNP 4_CD and_CC IL-_NNP 10_CD expression_NN also_RB were_VBD
          examined_VBN in_IN arthritic_JJ mice_NNS treated_VBN with_IN Ad-m_NNP IL-_NNP 4_CD at_IN day_NN
          35_CD after_IN injection_NN ._. As_IN shown_VBN in_IN Figure_NN 5_CD a_DT ,_, a_DT slight_JJ
          increase_NN in_IN IL-_NNP 4_CD expression_NN was_VBD observed_VBN in_IN that_DT
          correlated_JJ with_IN the_DT dose_NN of_IN Ad-m_NNP IL-_NNP 4_CD (_( Fig_NNP ._. 5_LS a_DT )_) ._. A_DT similar_JJ
          increase_NN at_IN day_NN 35_CD was_VBD also_RB observed_VBN in_IN naïve_NN mice_NNS (_( data_NNS
          not_RB shown_VBN )_) ._. In_IN addition_NN ,_, a_DT significant_JJ dose-dependent_JJ
          increase_NN in_IN the_DT level_NN of_IN endogenous_JJ IL-_NNP 10_CD 35_CD days_NNS after_IN
          Ad-m_NNP IL-_NNP 4_CD administration_NN was_VBD observed_VBN in_IN the_DT CIA-treated_NNP
          animals_NNS (_( Fig_NNP ._. 5_LS b_SYM )_) ._. These_DT results_NNS demonstrated_VBN that_IN IL-_NNP 4_CD
          transgene_NN expression_NN was_VBD detectable_JJ for_IN up_IN to_TO 5_CD weeks_NNS
          after_IN Ad-m_NNP IL-_NNP 4_CD delivery_NN and_CC that_IN IL-_NNP 4_CD was_VBD able_JJ to_TO induce_VB
          the_DT production_NN of_IN endogenous_JJ IL-_NNP 10_CD in_IN the_DT joints_NNS of_IN both_DT
          naïve_NN and_CC immunized_JJ mice_NNS ._. In_IN addition_NN ,_, expression_NN of_IN IL-_NNP 4_CD
          resulted_VBD in_IN a_DT twofold_NN increase_NN in_IN the_DT level_NN of_IN endogenous_JJ
          IL-_NNP 1_CD Ra_NNP (_( data_NNS not_RB shown_VBN )_) ._. In_IN contrast_NN ,_, periarticular_NN
          injection_NN of_IN Ad-m_NNP IL-_NNP 10_CD did_VBD not_RB affect_VB the_DT level_NN of_IN
          expression_NN of_IN endogenous_JJ levels_NNS of_IN IL-_NNP 4_CD (_( Fig_NNP ._. 4_LS a_DT )_) and_CC
          IL-_NNP 1_CD Ra_NNP (_( data_NNS not_RB shown_VBN )_) ._. Taken_VBN together_RB ,_, these_DT results_NNS
          suggest_VBP that_IN the_DT therapeutic_JJ effects_NNS of_IN exogenous_JJ IL-_NNP 4_CD
          could_MD be_VB mediated_JJ in_IN part_NN through_IN the_DT induction_NN of_IN
          endogenous_JJ IL-_NNP 4_CD and_CC IL-_NNP 1_CD Ra_NNP ._.
        
        
          Delay_NNP of_IN disease_NN onset_NN by_IN systemic_JJ Ad-m_NNP IL-_NNP 4_CD
          administration_NN
          The_DT administration_NN of_IN recombinant_JJ IL-_NNP 4_CD protein_NN
          systemically_RB has_VBZ been_VBN shown_VBN to_TO be_VB therapeutic_JJ in_IN murine_NN
          CIA_NNP models_NNS if_IN given_VBN before_IN onset_NN of_IN disease_NN onset_NN ._. To_TO
          examine_VB the_DT effect_NN of_IN systemic_JJ IL-_NNP 4_CD delivered_VBN by_IN gene_NN
          transfer_NN ,_, 10_CD 9_CD particles_NNS of_IN Ad-m_NNP IL-_NNP 4_CD were_VBD administered_VBN
          intravenously_RB by_IN tail_NN vein_NN injection_NN of_IN the_DT
          collagen-immunized_JJ mice_NNS on_IN the_DT day_NN after_IN
          lipopolysaccharide_NN injection_NN ._. Whereas_IN the_DT immunized_JJ mice_NNS
          injected_VBN with_IN Ad-e_NNP GFP_NNP showed_VBD disease_NN onset_NN on_IN day_NN 3_CD after_IN
          lipopolysaccharide_NN injection_NN ,_, IL-_NNP 4_CD -_: treated_VBN mice_NNS showed_VBD a_DT
          delay_NN in_IN disease_NN onset_NN (_( Fig_NNP ._. 6_CD a_DT )_) as_RB well_RB as_IN a_DT reduction_NN
          in_IN the_DT total_JJ number_NN of_IN arthritic_JJ paws_NNS (_( Fig_NNP ._. 6_CD c_SYM )_) ._. In_IN
          addition_NN ,_, seven_CD out_IN of_IN the_DT 15_CD Ad-m_NNP IL-_NNP 4_CD -_: treated_VBN mice_NNS were_VBD
          disease-free_JJ for_IN up_IN to_TO 10_CD days_NNS after_IN lipopolysaccharide_NN
          injection_NN ,_, and_CC two_CD mice_NNS were_VBD disease_NN free_JJ at_IN the_DT end_NN of_IN
          the_DT experiment_NN on_IN day_NN 65_CD ._. In_IN addition_NN ,_, systemic_JJ injection_NN
          of_IN Ad-m_NNP IL-_NNP 4_CD suppressed_VBD the_DT severity_NN of_IN arthritis_NN in_IN the_DT
          CIA_NNP mice_NNS according_VBG to_TO arthritis_NN index_NN (_( Fig_NNP ._. 6_CD b_SYM )_) ._. Thus_RB ,_,
          systemic_JJ delivery_NN of_IN IL-_NNP 4_CD by_IN adenovirus-mediated_JJ gene_NN
          transfer_NN is_VBZ able_JJ to_TO reduce_VB the_DT onset_NN and_CC severity_NN of_IN
          early-stage_JJ disease_NN ._.
        
        
          IL-_NNP 4_CD and_CC IL-_NNP 10_CD expression_NN in_IN sera_NN of_IN CIA_NNP mice_NNS
          administered_VBN Ad-m_NNP IL-_NNP 4_CD systemically_RB
          To_TO examine_VB the_DT duration_NN of_IN IL-_NNP 4_CD expression_NN as_RB well_RB as_IN
          induction_NN of_IN endogenous_JJ IL-_NNP 10_CD expression_NN ,_, serum_NN was_VBD
          collected_VBN from_IN the_DT mice_NNS and_CC tested_VBN for_IN levels_NNS of_IN IL-_NNP 4_CD and_CC
          IL-_NNP 10_CD (_( Fig_NNP ._. 7_CD )_) ._. An_DT elevated_VBD level_NN of_IN IL-_NNP 4_CD was_VBD detected_VBN in_IN
          on_IN day_NN 7_CD (_( Fig_NNP ._. 7_CD a_DT )_) and_CC on_IN day_NN 30_CD (_( Fig_NNP ._. 7_CD c_SYM )_) after_IN IL-_NNP 4_CD
          injection_NN ._. In_IN addition_NN ,_, although_IN there_EX was_VBD no_DT observed_VBN
          increase_NN in_IN the_DT expression_NN of_IN IL-_NNP 10_CD in_IN the_DT sera_NN at_IN day_NN 7_CD
          after_IN systemic_JJ delivery_NN of_IN IL-_NNP 4_CD (_( Fig_NNP ._. 7_CD b_SYM )_) ,_, IL-_NNP 10_CD was_VBD
          elevated_VBD in_IN the_DT sera_NN at_IN day_NN 35_CD (_( Fig_NNP ._. 7_CD d_SYM )_) ._. In_IN contrast_NN ,_,
          the_DT levels_NNS of_IN IL-_NNP 4_CD and_CC IL-_NNP 10_CD in_IN the_DT saline_NN or_CC
          Ad-e_NNP GFP-treated_NNP control_NN groups_NNS were_VBD not_RB significantly_RB
          above_IN background_NN after_IN either_DT or_CC local_JJ Ad-m_NNP IL-_NNP 4_CD delivery_NN ._.
          Thus_RB ,_, the_DT early_JJ therapeutic_JJ effects_NNS of_IN IL-_NNP 4_CD after_IN
          systemic_JJ delivery_NN most_RBS likely_JJ are_VBP not_RB mediated_JJ by_IN IL-_NNP 10_CD ._.
          In_IN contrast_NN ,_, it_PRP is_VBZ possible_JJ that_IN the_DT therapeutic_JJ effects_NNS
          of_IN IL-_NNP 4_CD after_IN local_JJ injection_NN are_VBP conferred_VBD in_IN part_NN by_IN
          IL-_NNP 10_CD ._.
        
      
      
        Discussion_NNP
        Gene_NNP therapy_NN represents_VBZ a_DT novel_NN approach_NN for_IN delivery_NN of_IN
        therapeutic_JJ agents_NNS to_TO joints_NNS in_IN order_NN to_TO treat_VB the_DT
        pathologies_NNS associated_VBN with_IN RA_NNP and_CC osteoarthritis_NNS ,_, as_RB well_RB
        as_IN other_JJ disorders_NNS of_IN the_DT joints_NNS ._. Previously_RB ,_, we_PRP and_CC others_NNS
        have_VBP shown_VBN that_IN local_JJ 
        ex_FW vivo_NN and_CC 
        in_IN vivo_NN gene_NN transfer_NN of_IN v-_NN IL-_NNP 10_CD ,_,
        IL-_NNP 1_CD Ra_NNP ,_, IFN-γ_NNP ,_, soluble_JJ IL-_NNP 1_CD receptor_NN ,_, and_CC soluble_JJ TNF_NNP
        receptor_NN are_VBP able_JJ to_TO block_VB certain_JJ intra-articular_JJ
        pathologies_NNS in_IN rabbit_NN ,_, rat_NN ,_, and_CC murine_NN models_NNS of_IN arthritis_NN ._.
        IL-_NNP 4_CD ,_, like_IN IL-_NNP 10_CD ,_, is_VBZ a_DT Th_NNP 2_CD cytokine_NN that_WDT has_VBZ been_VBN
        demonstrated_VBN to_TO be_VB therapeutic_JJ for_IN the_DT treatment_NN of_IN
        arthritis_NN after_IN systemic_JJ administration_NN of_IN recombinant_JJ
        protein_NN ._.
        In_IN the_DT present_JJ study_NN we_PRP examined_VBD the_DT ability_NN of_IN local_JJ
        periarticular_NN gene_NN transfer_NN of_IN IL-_NNP 4_CD to_TO treat_VB established_VBN
        murine_NN CIA_NNP ._. We_PRP demonstrated_VBD that_IN both_DT local_JJ and_CC systemic_JJ
        administration_NN of_IN Ad-m_NNP IL-_NNP 4_CD resulted_VBD in_IN a_DT reduction_NN in_IN the_DT
        severity_NN of_IN established_VBN and_CC early-stage_JJ arthritis_NN ,_,
        respectively_RB ,_, as_RB well_RB as_IN in_IN the_DT number_NN of_IN arthritic_JJ paws_NNS ._.
        In_IN addition_NN ,_, the_DT local_JJ gene_NN transfer_NN of_IN Ad-m_NNP IL-_NNP 4_CD reduced_VBN
        histologic_JJ signs_NNS of_IN inflammation_NN as_RB well_RB as_IN bone_NN erosion_NN ._.
        Previous_JJ experiments_NNS have_VBP shown_VBN that_DT gene_NN transfer_NN of_IN IL-_NNP 10_CD
        and_CC IL-_NNP 1_CD and_CC TNF_NNP inhibitors_NNS at_IN the_DT time_NN of_IN disease_NN
        initiation_NN (_( day_NN 28_CD )_) was_VBD therapeutic_JJ ._. However_RB ,_, delivery_NN of_IN
        these_DT agents_NNS after_IN disease_NN onset_NN appeared_VBD to_TO have_VB only_RB
        limited_JJ therapeutic_JJ effect_NN ._. In_IN contrast_NN ,_, the_DT present_JJ
        results_NNS demonstrate_VBP that_IN local_JJ IL-_NNP 4_CD delivery_NN was_VBD able_JJ
        partially_RB to_TO reverse_VB progression_NN of_IN established_VBN disease_NN
        after_IN local_JJ periarticular_NN injection_NN ._.
        Interestingly_RB ,_, local_JJ and_CC systemic_JJ expression_NN of_IN IL-_NNP 4_CD
        resulted_VBD in_IN an_DT increase_NN in_IN the_DT level_NN of_IN endogenous_JJ IL-_NNP 10_CD as_RB
        well_RB as_IN IL-_NNP 1_CD Ra_NNP ._. Previous_JJ reports_NNS have_VBP shown_VBN that_IN an_DT
        additive_JJ or_CC possible_JJ synergistic_JJ therapeutic_JJ effect_NN can_MD be_VB
        achieved_VBN in_IN animal_NN models_NNS of_IN arthritis_NN with_IN combined_VBN
        treatment_NN with_IN recombinant_JJ IL-_NNP 4_CD and_CC IL-_NNP 10_CD ._. Treatment_NNP of_IN
        mice_NNS with_IN IL-_NNP 4_CD and_CC IL-_NNP 10_CD results_NNS in_IN reduction_NN in_IN TNF-α_NNP and_CC
        IL-_NNP 1_CD β_NN production_NN with_IN a_DT concomitant_NN shift_NN in_IN the_DT
        IL-_NNP 1_CD Ra_NNP :_: IL-_NNP 1_CD ratio_NN [_NN 18_CD ,_, 19_CD ]_NN ._. The_DT fact_NN that_IN the_DT therapeutic_JJ
        effects_NNS of_IN IL-_NNP 4_CD and_CC IL-_NNP 10_CD are_VBP potentially_RB synergistic_JJ is_VBZ
        possibly_RB due_JJ to_TO the_DT fact_NN that_IN they_PRP suppress_VB proinflammatory_NN
        mediator_NN production_NN through_IN different_JJ mechanisms_NNS ._. IL-_NNP 4_CD is_VBZ
        able_JJ to_TO block_VB transcription_NN of_IN TNF_NNP and_CC IL-_NNP 1_CD genes_NNS ,_, whereas_IN
        IL-_NNP 10_CD stimulates_NNS degradation_NN of_IN TNF_NNP and_CC IL-_NNP 1_CD β_NN mRNAs_NNS [_NN 20_CD ]_NN ._.
        Thus_RB ,_, it_PRP is_VBZ likely_JJ that_IN the_DT therapeutic_JJ effects_NNS we_PRP observed_VBD
        after_IN local_JJ injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD are_VBP due_JJ to_TO both_DT exogenous_JJ
        IL-_NNP 4_CD and_CC endogenous_JJ IL-_NNP 10_CD production_NN ._. However_RB ,_, the_DT delayed_VBN
        induction_NN of_IN IL-_NNP 10_CD after_IN systemic_JJ administration_NN of_IN
        Ad-m_NNP IL-_NNP 4_CD suggests_VBZ that_IN the_DT initial_JJ therapeutic_JJ effects_NNS are_VBP
        not_RB conferred_VBD by_IN IL-_NNP 10_CD ._.
        A_DT mechanism_NN whereby_WRB IL-_NNP 4_CD may_MD alter_VB IL-_NNP 10_CD and_CC IL-_NNP 1_CD Ra_NNP
        levels_NNS could_MD involve_VB the_DT regulation_NN of_IN transcription_NN
        factors_NNS that_WDT regulate_VB the_DT respective_JJ genes_NNS for_IN these_DT
        cytokines_NNS ._. In_IN particular_JJ ,_, nuclear_JJ factor-κ_JJ B_NNP and_CC signal_NN
        transducer_NN and_CC activator_NN of_IN transcription-_NN 6_CD are_VBP important_JJ
        for_IN conferring_VBG transcriptional_NN regulation_NN by_IN IL-_NNP 4_CD ._. Signal_NNP
        transducer_NN and_CC activator_NN of_IN transcription-_NN 6_CD ,_, after_IN tyrosine_NN
        phosphorylation_NN ,_, can_MD bind_NN directly_RB to_TO nuclear_JJ factor-κ_JJ B_NNP [_NN
        21_CD ]_NN ,_, resulting_VBG in_IN synergic_JJ activation_NN in_IN certain_JJ cell_NN
        types_NNS ._.
        The_DT present_JJ results_NNS suggest_VBP that_DT gene_NN transfer_NN of_IN IL-_NNP 4_CD
        can_MD stimulate_VB expression_NN of_IN endogenous_JJ cytokines_NNS ,_, such_JJ as_IN
        IL-_NNP 10_CD and_CC IL-_NNP 1_CD Ra_NNP ,_, as_RB well_RB as_RB possibly_RB endogenous_JJ IL-_NNP 4_CD
        expression_NN ._. Endogenous_NNP IL-_NNP 10_CD ,_, which_WDT can_MD be_VB induced_VBN by_IN IL-_NNP 4_CD ,_,
        is_VBZ a_DT natural_JJ suppressor_NN of_IN a_DT number_NN of_IN inflammatory_JJ
        responses_NNS ._. Inhibition_NNP of_IN endogenous_JJ IL-_NNP 10_CD with_IN neutralizing_VBG
        antibodies_NNS enhanced_VBD endotoxic_JJ shock_NN ,_, IgG_NNP immune_JJ
        complex-induced_JJ lung_NN injury_NN ,_, and_CC the_DT severity_NN of_IN CIA_NNP [_NN 22_CD ,_,
        23_CD ,_, 24_CD ,_, 25_CD ]_NN ._. Periarticular_NNP delivery_NN of_IN murine_NN or_CC viral_JJ
        IL-_NNP 10_CD by_IN gene_NN transfer_NN resulted_VBN in_IN the_DT inhibition_NN of_IN CIA_NNP in_IN
        mouse_NN models_NNS [_NN 10_CD ,_, 26_CD ]_NN if_IN delivered_VBN before_IN or_CC at_IN the_DT time_NN
        of_IN disease_NN onset_NN ._. The_DT present_JJ results_NNS are_VBP also_RB consistent_JJ
        with_IN the_DT observation_NN that_IN IL-_NNP 4_CD ,_, but_CC not_RB IL-_NNP 10_CD ,_, has_VBZ been_VBN
        shown_VBN to_TO enhance_VB the_DT production_NN of_IN IL-_NNP 1_CD Ra_NNP by_IN RA_NNP synovial_NN
        cells_NNS [_NN 14_CD ,_, 27_CD ]_NN ._.
        IL-_NNP 4_CD is_VBZ a_DT potent_JJ mediator_NN in_IN shifting_VBG the_DT balance_NN of_IN
        Th_NNP 1_CD /_NN Th_NNP 2_CD cells_NNS and_CC skewing_VBG the_DT production_NN of_IN antibody_NN
        subtypes_NNS [_NN 28_CD ]_NN ._. Th_NNP 2_CD effector_NN cell_NN differentiation_NN also_RB is_VBZ
        dependent_JJ on_IN the_DT presence_NN of_IN IL-_NNP 4_CD during_IN priming_VBG [_NN 29_CD ]_NN ._.
        Blocking_NNP endogenous_JJ IL-_NNP 4_CD using_VBG neutralizing_VBG antibodies_NNS has_VBZ
        been_VBN shown_VBN [_NN 30_CD ]_NN to_TO result_VB not_RB only_RB in_IN the_DT absence_NN of_IN T_NN
        cells_NNS with_IN a_DT Th_NNP 2_CD -_: like_IN phenotype_NN ,_, but_CC also_RB in_IN the_DT appearance_NN
        of_IN T_NN cells_NNS producing_VBG IL-_NNP 2_CD and_CC IFN-γ_NNP after_IN restimulation_NN ._.
        IL-_NNP 4_CD is_VBZ also_RB able_JJ to_TO skew_NN the_DT production_NN of_IN antibody_NN
        subtype_NN [_NN 28_CD ]_NN ._. However_RB ,_, we_PRP have_VBP shown_VBN that_DT anticollagen_NN
        antibody_NN levels_NNS are_VBP already_RB very_RB high_JJ at_IN day_NN 30_CD after_IN
        immunization_NN and_CC that_IN IL-_NNP 4_CD treatment_NN did_VBD not_RB significantly_RB
        change_VB these_DT elevated_VBD levels_NNS (_( data_NNS not_RB shown_VBN )_) ._. In_IN addition_NN ,_,
        we_PRP did_VBD not_RB observe_VB significant_JJ differences_NNS between_IN IgG_NNP
        isotypes_NNS in_IN the_DT control_NN and_CC Ad-m_NNP IL-_NNP 4_CD treated_VBN mice_NNS (_( data_NNS not_RB
        shown_VBN )_) ._. Thus_RB ,_, the_DT mechanisms_NNS through_IN which_WDT local_JJ and_CC
        systemic_JJ IL-_NNP 4_CD administration_NN are_VBP able_JJ to_TO suppress_VB CIA_NNP are_VBP
        still_RB unclear_JJ ._.
        We_PRP have_VBP demonstrated_VBN previously_RB that_DT periarticular_NN
        injection_NN of_IN adenovirus-mediated_JJ gene_NN transfer_NN of_IN v-_NN IL-_NNP 10_CD
        into_IN the_DT hind_NN paws_NNS of_IN mice_NNS with_IN early-stage_JJ arthritis_NN was_VBD
        able_JJ to_TO confer_VB a_DT therapeutic_JJ effect_NN in_IN the_DT untreated_JJ front_JJ
        paws_NNS ._. Similarly_RB ,_, administration_NN of_IN v-_NN IL-_NNP 10_CD into_IN one_CD knee_NN of_IN
        rabbits_NNS with_IN antigen-induced_JJ arthritis_NN was_VBD able_JJ to_TO confer_VB a_DT
        therapeutic_JJ effect_NN in_IN the_DT contralateral_NN untreated_JJ knee_NN ._.
        This_DT observed_VBN contralateral_NN effect_NN was_VBD not_RB limited_VBN to_TO
        v-_NN IL-_NNP 10_CD ,_, in_IN that_DT coadministration_NN of_IN adenoviral_NN vectors_NNS
        expressing_VBG soluble_JJ IL-_NNP 1_CD and_CC soluble_JJ TNF_NNP receptors_NNS also_RB
        conferred_VBD a_DT similar_JJ protective_JJ effect_NN to_TO untreated_JJ knees_NNS ._.
        Although_IN the_DT mechanism_NN of_IN the_DT contralateral_NN effect_NN is_VBZ
        unclear_JJ ,_, we_PRP have_VBP demonstrated_VBN that_IN adoptive_JJ transfer_NN of_IN
        dendritic_JJ cells_NNS from_IN animals_NNS treated_VBN with_IN
        adenovirus-mediated_JJ gene_NN transfer_NN of_IN v-_NN IL-_NNP 10_CD to_TO untreated_JJ
        immunized_JJ animals_NNS is_VBZ able_JJ to_TO confer_VB a_DT therapeutic_JJ effect_NN
        (_( unpublished_JJ data_NNS )_) ._. Thus_RB ,_, it_PRP is_VBZ possible_JJ that_IN local_JJ
        expression_NN of_IN v-_NN IL-_NNP 10_CD or_CC IL-_NNP 1_CD and_CC TNF_NNP inhibitors_NNS modulates_NNS
        the_DT activity_NN of_IN dendritic_JJ cells_NNS ._. However_RB ,_, although_IN v-_NN IL-_NNP 10_CD
        is_VBZ able_JJ to_TO block_VB early-stage_JJ disease_NN ,_, it_PRP is_VBZ ineffective_JJ in_IN
        reversing_VBG established_VBN disease_NN ._. In_IN contrast_NN ,_, periarticular_NN
        injection_NN of_IN Ad-m_NNP IL-_NNP 4_CD was_VBD able_JJ to_TO reverse_VB pathology_NN in_IN
        established_VBN disease_NN not_RB only_RB in_IN the_DT treated_VBN hind_NN paws_NNS ,_, but_CC
        also_RB in_IN the_DT untreated_JJ front_JJ paws_NNS ._. Interestingly_RB ,_, we_PRP have_VBP
        observed_VBN that_IN intravenous_JJ injection_NN of_IN naïve_NN dendritic_JJ
        cells_NNS ,_, genetically_RB modified_VBN to_TO express_VB IL-_NNP 4_CD ,_, is_VBZ able_JJ to_TO
        effectively_RB treat_VB established_VBN arthritis_NN by_IN inhibiting_VBG the_DT
        Th_NNP 1_CD response_NN (_( unpublished_JJ data_NNS )_) ._.
        During_IN the_DT preparation_NN of_IN this_DT manuscript_NN ,_, a_DT similar_JJ
        study_NN using_VBG a_DT recombinant_JJ Ad-m_NNP IL-_NNP 4_CD vector_NN for_IN treatment_NN of_IN
        murine_NN CIA_NNP was_VBD reported_VBN [_NN 31_CD ]_NN ._. However_RB ,_, the_DT vector_NN was_VBD
        administered_VBN before_IN onset_NN of_IN disease_NN into_IN knee_NN joints_NNS ,_,
        whereas_IN the_DT vector_NN in_IN the_DT present_JJ study_NN was_VBD injected_VBN after_IN
        disease_NN onset_NN into_IN ankle_NN joints_NNS ._. Similar_JJ to_TO the_DT present_JJ
        results_NNS ,_, in_IN that_DT study_NN local_JJ injection_NN of_IN the_DT recombinant_JJ
        Ad-m_NNP IL-_NNP 4_CD vector_NN resulted_VBD in_IN a_DT reduction_NN in_IN bone_NN erosion_NN and_CC
        a_DT reduction_NN in_IN cartilage_NN degradation_NN ._. However_RB ,_, unlike_IN the_DT
        present_JJ results_NNS ,_, no_DT effect_NN on_IN joint_JJ inflammation_NN was_VBD
        observed_VBN ._. Moreover_RB ,_, in_IN the_DT present_JJ report_NN we_PRP demonstrated_VBD
        that_IN both_DT local_JJ and_CC systemic_JJ injection_NN resulted_VBD in_IN
        induction_NN of_IN endogenous_JJ IL-_NNP 10_CD ._. Given_VBN the_DT ability_NN of_IN IL-_NNP 4_CD to_TO
        reverse_VB established_VBN disease_NN partially_RB ,_, our_PRP$ studies_NNS ,_, as_RB well_RB
        as_IN those_DT of_IN others_NNS ,_, support_NN the_DT potential_JJ application_NN of_IN
        IL-_NNP 4_CD gene_NN therapy_NN for_IN the_DT clinical_JJ treatment_NN of_IN RA_NNP ._.
      
    
  
